Article Sidebar

PDF
Date Published: 26/05/2023
Abstract Views: 95
Views PDF: 105
DOI: https://doi.org/10.51298/vmj.v526i1B.5444
Issue
Vol. 526 No. 1B (2023)
Section
Các bài báo
How to Cite
Lê, Q. N., Nguyễn, X. K. ., & Dương , Q. H. . (2023). STAT5B rs6503961 GENE POLYMORPHISM IN PATIENTS WITH HEPATITIS B VIRUS - RELATED HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 526(1B). https://doi.org/10.51298/vmj.v526i1B.5444

STAT5B rs6503961 GENE POLYMORPHISM IN PATIENTS WITH HEPATITIS B VIRUS - RELATED HEPATOCELLULAR CARCINOMA

Quang Nhựt Lê1,2, Xuân Kiên Nguyễn2, Quang Huy Dương 2,
1 Tay Do university
2 Vietnam Military Medical Academy

Main Article Content

Abstract

Objectives: Determine the genotype prevalence of STAT5b rs6503691 polymorphism and the relationship with the cancer risk in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Subjects and methods: A cross-sectioaaV-related HCC patients compared with 86 HBV-related cirrhotic patients and 195 control subjects at 108 Military Central Hospital, 103 Military Hospital, and Cantho General Hospital from 7/2017 - 8/2020. Analysis of STAT5b rs6503691 gene polymorphism from 5-mL peripheral venous blood sample by PCR-RFLP method at Institute of Biomedicine and Pharmacy-Vietnam Military Medical University. Result: CC genotype of STAT5b rs6503691 polymorphism accounted for the ratio of 49.7% in patients with HCC, higher than the prevalence in cirrhotic patients (47.7%) and the control (40,5%), while the TT genotype accounted for the lowest ratio in patients with HBV-related cirrhosis (7.0%), however, the difference has not been statistical significance. Conclusion: There is not significant association between STAT5b rs6503691 polymorphism with the risk of HBV-related HCC.

Article Details

Keywords

STAT5b polymorphism, Hepatocellular carcinoma.

References

1. Sung H., Ferlay J., Siegel R.L. et al. (2021). Global Cancer Statistics 2020 GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71: 209–249.
2. Marrero J.A., Kulik L.M., Sirlin C.B. et al. (2018), Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases., Hepatology. 68 (2): 723-750.
3. European Association for the Study of the Liver (2017), EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 67: 370–398.
4. Alqahtani A., Khan Z., Alloghbi A. et al. (2019), Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Medicine, 55(9): 526–547.
5. Thomas S.J., Snowden J.A., Zeidler M.P. et al. (2015), The role of JAK/STAT signaling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer., 113(3): 365–371.
6. Dong Z., Chen Y., Yang C. et al. (2019). STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma. OncoTargets and Therapy. 12: 7175–7191.
7. Zhao L., Zhang Q., Luan X. et al. (2015). STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes. Int J Clin Exp Pathol., 8(2): 2033-2038.
8. Vaclavicek A., Bermejo J.L., Schmutzler R.K. et al. (2007). Polymorphisms in the Janus kinase 2 (JAK)/ signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocrine-Related Cancer, 14: 267–277.
9. Trifa A.P., Cucuianu A., Popp R.A. et al. (2012). No association between the STAT5b rs6503691 (C>T) SNP and myeloproliferative neoplasms. European Journal of Haematology, 90: 257–258.
10. Bộ Y tế (2012). Hướng dẫn chẩn đoán và điều trị ung thư tế bào gan nguyên phát, Ban hành kèm theo Quyết định số: 5250/QĐ-BYT ngày 28 tháng 12 năm 2012 của Bộ trưởng Bộ Y tế.